RxDoctor Payments Data

Wayne Barksdale, MD

Family Medicine · Olla, LANPI 1912902453

Payments from drug & device makers

$921in general payments, 2019–2025

Across 53 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$463
  • Pfizer$93
  • Novo Nordisk$73
  • Lilly USA, LLC$65
  • Viatris Specialty LLC$59
  • Mylan Specialty L.p.$38
  • plus $131 from 6 others

What the payments were for

  • Food & beverage$921100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$921 in reported general payments places this provider in the 55th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$9,108
Medicare patients
69
Services billed
151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide89$86,766
EliquisApixaban139$86,190
JardianceEmpagliflozin121$84,300
MounjaroTirzepatide55$54,926
JanuviaSitagliptin Phosphate71$51,396
TrulicityDulaglutide50$46,769
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$36,813
LinzessLinaclotide45$32,392
XareltoRivaroxaban43$32,181
JanumetSitagliptin Phos/Metformin Hcl38$16,616
MyrbetriqMirabegron26$14,087
MultaqDronedarone Hcl12$9,005
TradjentaLinagliptin12$6,342
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$6,297
Potassium Chloride427$6,099

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$65$101,695105 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$15$96,938146 claims
PfizerEliquis, Premarin$93$88,458151 claims
Novo NordiskOzempic$73$86,76689 claims
GSKTrelegy Ellipta, Breo Ellipta$15$42,19267 claims
AbbVieLinzess$463$32,39245 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Olla

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →